219 terminated. 219 Phase 2, 77 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 219 | Terminated 219 |
| Phase 1 | 77 | Terminated 77 |
| Phase 3 | 6 | Terminated 6 |
Follow Adnexal Diseases: new trials by email Literature Review of Adnexal Diseases trials Research Report on Adnexal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Engineered Immune Effectors Against Ovarian Cancer OC-CTLs - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Genetically Modified T Cells Against Ovarian Cancer OC-IgT cells - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-05-01 | 2026-11-03 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers AUR109 200mg, AUR109 300mg, AUR109 400mg - Ovarian Cancer, Colorectal Cancer | Phase 2 | Terminated | Aurigene Discovery Technologies Limited | 29 | 2024-11-09 | 2026-04-17 |
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer CBX-12 - Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma | Phase 2 | Terminated | Cybrexa Therapeutics | 40 | 2024-09-25 | 2026-08-20 |
| Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy Promitil - Cancer of Ovary, Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Lipomedix Pharmaceuticals Inc. | 19 | 2024-06-13 | 2026-01-09 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors VIO-01 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Terminated | Valerio Therapeutics | 6 | 2024-01-10 | 2025-03-17 |
| PRO1107 in Patients With Advanced Solid Tumors GEN1107 - Endometrial Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Genmab | 33 | 2024-01-03 | 2026-10-29 |
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors TNG348, Olaparib - Breast Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Tango Therapeutics, Inc. | 7 | 2023-12-08 | 2024-08-13 |
| [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer 68Ga-FAPi-46 - Ovarian Cancer | Phase 2 | Terminated | Aalborg University Hospital | 20 | 2023-11-17 | 2026-05-27 |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
| ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab - Ovarian Cancer | Phase 2 | Terminated | USWM CT, LLC | 21 | 2023-06-26 | 2026-10-19 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation Bevacizumab, Niraparib - Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Terminated | University of Oklahoma | 9 | 2023-02-15 | 2026-06-03 |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors MDK-703, Checkpoint Inhibitor, Immune - Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Terminated | Medikine, Inc. | 26 | 2023-02-08 | 2024-05-08 |
| A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD) - Neoplasms, Ovarian | Phase 2 | Terminated | Bristol-Myers Squibb | 106 | 2023-02-01 | 2026-10-28 |
| A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase) - Neoplasm, Ovarian, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Avenge Bio, Inc | 14 | 2022-12-09 | 2024-04-24 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors NC410, pembrolizumab - Advanced or Metastatic Solid Tumors, Microsatellite Instability Low | Phase 1 / Phase 2 | Terminated | NextCure, Inc. | 97 | 2022-10-06 | 2026-08-13 |
Showing 20 of 219. Sign in to see all of them.
Ovarian Neoplasms (188) · Carcinoma, Ovarian Epithelial (58) · Fallopian Tube Neoplasms (58) · Breast Neoplasms (30) · Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (19) · Neoplasm Metastasis (18) · Pancreatic Neoplasms (16) · Colorectal Neoplasms (15) · Uterine Cervical Neoplasms (15) · Endometrial Neoplasms (14) · Recurrence (12) · Sarcoma (12) · Prostatic Neoplasms (11) · Stomach Neoplasms (11)
Female Urogenital Diseases (219) · Female Urogenital Diseases and Pregnancy Complications (219) · Genital Diseases (219) · Genital Diseases, Female (219) · Urogenital Diseases (219) · Endocrine System Diseases (217) · Gonadal Disorders (217) · Ovarian Diseases (214) · Urogenital Neoplasms (211) · Endocrine Gland Neoplasms (210) · Neoplasms by Site (210) · Genital Neoplasms, Female (209) · Neoplasms (197) · Neoplasms by Histologic Type (96)
Paclitaxel (32) · Carboplatin (28) · Topotecan (13) · Gemcitabine (12) · Bevacizumab (11) · liposomal doxorubicin (11) · Cyclophosphamide (10) · pembrolizumab (9) · Cisplatin (7) · Nivolumab (7) · Docetaxel (6) · Taxes (6) · fludarabine (5) · niraparib (5) · rucaparib (5)
National Cancer Institute (NCI) (13) · Gynecologic Oncology Group (10) · M.D. Anderson Cancer Center (9) · Masonic Cancer Center, University of Minnesota (5) · Dana-Farber Cancer Institute (4) · Incyte Corporation (3) · Mayo Clinic (3) · NextCure, Inc. (3) · Pfizer (3) · Unither Pharmaceuticals (3) · pharmaand GmbH (3) · Beth Israel Deaconess Medical Center (2) · Bracco Diagnostics, Inc (2) · City of Hope Medical Center (2) · Deciphera Pharmaceuticals, LLC (2)
United States (174) · Canada (25) · Spain (16) · United Kingdom (15) · Australia (13) · Belgium (12) · France (12) · Germany (9) · Denmark (6) · Israel (6) · Italy (6) · Poland (6) · South Korea (6) · China (5) · Netherlands (5)
Amir A Jazaeri (2) · Brigitte E. Miller, MD (2) · David Barad, MD, MS (2) · Han Myint, MD (2) · Joan Walker, MD (2) · Jung-Min Lee, M.D. (2) · Lung-Ji Chang, PhD (2) · Melissa A. Geller, MD (2) · Norbert Gleicher, MD (2) · Paul Sabbatini, MD (2) · Peter G. Rose, MD (2)
PMID 37185961, PMID 12586591, PMID 12713990, PMID 12826431, PMID 14534883, PMID 14615449, PMID 15721430, PMID 15864277, PMID 16325893, PMID 17018256, PMID 17105988, PMID 17949799, PMID 19058838, PMID 19910321, PMID 20068097, PMID 20857170, PMID 22366591, PMID 23478059, PMID 23499151, PMID 24005613, PMID 24172094, PMID 24563078, PMID 24607285, PMID 24637997, PMID 24952307, PMID 25366685, PMID 26119093, PMID 26884585, PMID 28027849, PMID 28352185, PMID 28444622, PMID 28596446, PMID 28698009, PMID 28935273, PMID 29045540, PMID 29361470, PMID 29401246, PMID 31401903, PMID 31527168, PMID 31932108, PMID 33390325, PMID 33664128, PMID 33775123, PMID 34665631, PMID 35254001, PMID 35537408, PMID 36394849, PMID 36512649, PMID 36708371, PMID 37034617
2023 (3), 2008 (2), 2009 (2), 2016 (2), 2017 (2), U10CA027469 (2), 2018 (1), N01CM00100 (1), N01CM62204 (1), P30CA006927 (1), P30CA008748 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), P30CA033572 (1)